ELI LILLY AND COMPANY Proceeds from Sale of Productive Assets
ELI LILLY AND COMPANY (LLY) reported Proceeds from Sale of Productive Assets of $0 for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-20.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfProductiveAssets · last filed 2018-02-20
- ELI LILLY AND COMPANY proceeds from sale of productive assets for the quarter ending 2016-12-31 was $0.00.
- ELI LILLY AND COMPANY proceeds from sale of productive assets for the quarter ending 2016-09-30 was $0.00.
- ELI LILLY AND COMPANY proceeds from sale of productive assets for the quarter ending 2016-06-30 was $0.00.
- ELI LILLY AND COMPANY proceeds from sale of productive assets for the quarter ending 2016-03-31 was $0.00, a 100.00% decline year-over-year.
- ELI LILLY AND COMPANY proceeds from sale of productive assets for fiscal 2017 was $0.00.
- ELI LILLY AND COMPANY proceeds from sale of productive assets for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
- ELI LILLY AND COMPANY proceeds from sale of productive assets for fiscal 2015 was $410.00M.
- ELI LILLY AND COMPANY proceeds from sale of productive assets for fiscal 2014 was $0.00.
| Period end | Proceeds from Sale of Productive Assets 3 month | Proceeds from Sale of Productive Assets 6 month | Proceeds from Sale of Productive Assets 9 month | Proceeds from Sale of Productive Assets 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 10-K · filed 2018-02-20 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | $0.00 derived: sum of 2 quarters · filed 2018-02-20 | $0.00 derived: sum of 3 quarters · filed 2018-02-20 | $0.00 10-K · filed 2018-02-20 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-28 | $0.00 derived: sum of 2 quarters · filed 2016-10-28 | $0.00 10-Q · filed 2016-10-28 | $0.00 derived: sum of 4 quarters · filed 2018-02-20 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | $0.00 10-Q · filed 2016-07-28 | $0.00 derived: sum of 3 quarters · filed 2018-02-20 | $0.00 derived: sum of 4 quarters · filed 2018-02-20 |
| 2016-03-31 | $0.00 10-Q · filed 2016-04-29 | $0.00 derived: sum of 2 quarters · filed 2018-02-20 | $0.00 derived: sum of 3 quarters · filed 2018-02-20 | $0.00 derived: sum of 4 quarters · filed 2018-02-20 |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | $0.00 derived: sum of 2 quarters · filed 2018-02-20 | $0.00 derived: sum of 3 quarters · filed 2018-02-20 | $410.00M 10-K · filed 2018-02-20 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-28 | $0.00 derived: sum of 2 quarters · filed 2016-10-28 | $410.00M 10-Q · filed 2016-10-28 | $410.00M derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | $410.00M 10-Q · filed 2016-07-28 | $410.00M derived: sum of 3 quarters · filed 2017-02-21 | $410.00M derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-03-31 | $410.00M 10-Q · filed 2016-04-29 | $410.00M derived: sum of 2 quarters · filed 2017-02-21 | $410.00M derived: sum of 3 quarters · filed 2017-02-21 | $410.00M derived: sum of 4 quarters · filed 2017-02-21 |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | $0.00 derived: sum of 2 quarters · filed 2017-02-21 | $0.00 derived: sum of 3 quarters · filed 2017-02-21 | $0.00 10-K · filed 2017-02-21 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-30 | $0.00 derived: sum of 2 quarters · filed 2015-10-30 | $0.00 10-Q · filed 2015-10-30 | |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-30 | $0.00 10-Q · filed 2015-07-30 | ||
| 2014-03-31 | $0.00 10-Q · filed 2015-04-30 | |||
| 2013-12-31 | $0.00 10-K · filed 2016-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |